Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06467357 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
A Phase 3 study of Biliary Tract Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 620
- Enrollment target
- 20
- Study locations
NCT06467357: Recruiting Phase 3 study of Biliary Tract Cancer, sponsored by AstraZeneca.
NCT06467357 is a Phase 3 study of Biliary Tract Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 620 participants, above the 222-participant average among 36 other Biliary Tract Cancer trials with a reported enrollment target (179% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06467357, a Phase 3 study of Biliary Tract Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 620 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC.
Primary Outcome
Safety and tolerability will be evaluated by the proportion of treated patients with occurrence of AEs, SAEs and AESIs, as assessed by CTCAE v5.0.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG Trastuzumab deruxtecan
- DRUG Rilvegostomig
- DRUG Durvalumab
Study Locations (20)
California
- Research Site - Fullerton
- Research Site - La Jolla
- Research Site - Los Alamitos
- Research Site - Los Angeles
- Research Site - Los Angeles
- Research Site - San Francisco
Florida
- Research Site - Fort Myers
- Research Site - Jacksonville
- Research Site - St. Petersburg
- Research Site - Tampa
- Research Site - West Palm Beach
Arizona
- Research Site - Scottsdale
- Research Site - Tucson
- Research Site - Tucson
Illinois
- Research Site - Chicago
- Research Site - Niles
Georgia
- Research Site - Atlanta
Idaho
- Research Site - Coeur d'Alene
Maryland
- Research Site - Towson
Massachusetts
- Research Site - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 620 participants |
| Start Date | 2024-08-12 |
| Est. Completion | 2029-05-16 |
| Phase | Phase 3 |
What NCT06467357 shows while recruiting
NCT06467357 is an interventional study that assigns participants to a tested intervention. The registered 620 participants enrollment target is mid-sized for trials with a published cap, above the 222-participant average among 36 other Biliary Tract Cancer trials with a reported enrollment target (179% higher).
The record links to 1 condition, with Biliary Tract Cancer appearing as the primary indexed condition, and to 5 interventions - of which Cisplatin is the first listed.
NCT06467357 names 20 study sites across 8 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06467357 about?
NCT06467357 is a clinical study titled "Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer". The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC.
What is the current status of trial NCT06467357?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 620 participants. The study started on 2024-08-12. Estimated completion is 2029-05-16.
What conditions does trial NCT06467357 study?
This clinical trial studies the following conditions: Biliary Tract Cancer.
What interventions are being tested in trial NCT06467357?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), Trastuzumab deruxtecan (DRUG), Rilvegostomig (DRUG), Durvalumab (DRUG).
Who is sponsoring clinical trial NCT06467357?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06467357 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Biliary Tract Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06467357's enrollment target sits among peer trials
620 4th of 36 higher than 33 of 36 other Biliary Tract Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Biliary Tract Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
RECRUITING · Phase 3
-
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
RECRUITING · Phase 3
-
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
ACTIVE NOT RECRUITING · Phase 3
-
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
ACTIVE NOT RECRUITING · Phase 3
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02282969 · 620 participants
PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing
- NCT02838836 · 620 participants
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
- NCT05538910 · 620 participants · NA
Defining Neurobiological Links Between Substance Use and Mental Illness
- NCT05822466 · 620 participants · NA
Virtual Tai ji Quan Exercise to Prevent Falls in Older Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI